ID: MRFR/HC/6887-HCR | August 2022 | Region: Global | 111 Pages
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER
6.1. Overview
6.2. Peripheral Neuropathy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Autonomic Neuropathy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Proximal Neuropathy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5. Focal Neuropathy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT
7.1. Overview
7.2. Drugs
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.1. Analgesics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.2. Antidepressant
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.3. Anticonvulsants
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.2.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Transcutaneous Electrical Nerve Stimulation (TENS)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Retail Pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Online Pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1.1. Overview
10.1.2. Competitive Analysis
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Disorder Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. F. Hoffmann-La Roche Ltd
11.2.1. Company Overview
11.2.2. Disorder Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Eli Lilly and Company
11.3.1. Company Overview
11.3.2. Disorder Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Johnson & Johnson
11.4.1. Company Overview
11.4.2. Disorder Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. GlaxoSmithKline Plc
11.5.1. Company Overview
11.5.2. Disorder Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. LUPIN LIMITED
11.6.1. Company Overview
11.6.2. Disorder Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Glenmark Pharmaceuticals Limited
11.7.1. Company Overview
11.7.2. Disorder Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Depomed, Inc
11.8.1. Company Overview
11.8.2. Disorder Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Astellas Pharma Inc
11.9.1. Company Overview
11.9.2. Disorder Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Pfizer Inc
11.10.1. Company Overview
11.10.2. Disorder Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. MEDA Pharma GmBH & Co. KG
11.11.1. Company Overview
11.11.2. Disorder Overview
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)
TABLE 3 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 4 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 5 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 6 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION, 2020-2027(USD MILLION)
TABLE 7 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 8 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 9 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 10 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 11 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 12 US: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 13 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 14 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 15 CANADA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 16 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 17 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 18 LATIN AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 19 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 20 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 21 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 22 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 23 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 24 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 25 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 26 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 27 EASTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 28 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 29 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 30 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY DISORDER, 2020-2027(USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY TREATMENT, 2020-2027(USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET, BY END USER, 2020-2027(USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET
FIGURE 4 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY DISORDER, 2020 (%)
FIGURE 5 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY TREATMENT, 2020 (%)
FIGURE 6 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: DIABETIC NEUROPATHY TREATMENT MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: DIABETIC NEUROPATHY TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS
FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE
FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE
FIGURE 17 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS
FIGURE 18 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
FIGURE 19 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE
FIGURE 20 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 21 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 22 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 23 JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 24 JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 25 JOHNSON & JOHNSON: REGIONAL REVENUE
FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 29 LUPIN LIMITED: KEY FINANCIALS
FIGURE 30 LUPIN LIMITED: SEGMENTAL REVENUE
FIGURE 31 LUPIN LIMITED: REGIONAL REVENUE
FIGURE 32 GLENMARK PHARMACEUTICALS LIMITED: KEY FINANCIALS
FIGURE 33 GLENMARK PHARMACEUTICALS LIMITED: SEGMENTAL REVENUE
FIGURE 34 GLENMARK PHARMACEUTICALS LIMITED: REGIONAL REVENUE
FIGURE 35 DEPOMED, INC: KEY FINANCIALS
FIGURE 36 DEPOMED, INC: SEGMENTAL REVENUE
FIGURE 37 DEPOMED, INC: REGIONAL REVENUE
FIGURE 38 ASTELLAS PHARMA INC: KEY FINANCIALS
FIGURE 39 ASTELLAS PHARMA INC: SEGMENTAL REVENUE
FIGURE 40 ASTELLAS PHARMA INC: REGIONAL REVENUE
FIGURE 41 PFIZER INC: KEY FINANCIALS
FIGURE 42 PFIZER INC: SEGMENTAL REVENUE
FIGURE 43 PFIZER INC: REGIONAL REVENUE
FIGURE 44 MEDA PHARMA GMBH & CO. KG: KEY FINANCIALS
FIGURE 45 MEDA PHARMA GMBH & CO. KG: SEGMENTAL REVENUE
FIGURE 46 MEDA PHARMA GMBH & CO. KG: REGIONAL REVENUE
$7,719.92 million
5.80%
North America
2021-2030
Market Forecast
Global Diabetic Neuropathy Treatment Market is expected to cross USD 7,719.92 million by 2030 at a CAGR of 5.80%.
Market Synopsis
The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.
Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.
Market Influencer
The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.
Market Drivers
Market Restraints
Segmentation
By Disorder
By Treatment
By End-User
By Region
Key Players
Frequently Asked Questions (FAQ) :
Diabetic neuropathy treatment market was valued at USD 7,719.92 million in 2030.
The global market is expected to exhibit a strong 5.80% CAGR over the forecast period from 2020 to 2030.
The growing prevalence of diabetes is the major driver for the market.
The Americas are the leading regional market for diabetic neuropathy treatment due to the growing prevalence of diabetes in the region.
Leading players in the market include Abbott, Astellas Pharma, and Pfizer, among others.